News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website

 

Musella Foundation awards research grant for promising new brain tumor therapy

Al's Comment:

 This is an exciting new treatment. It is a next generation combination targeting 2 pathways:

1. an antiangiogenic drug - which blocks the formation of new blood vessels, which starves the tumor

2. Anti-invasion - so the tumor cells can't spread out looking for a new blood supply.

 


Posted on: 09/13/2013

The Musella Foundation For Brain Tumor Research & Information, Inc has awarded a $30,000 research grant for the project titled:

Anti-Cancer Activity of OKN-007 in Pediatric Gliomas.  This is an experimental treatment that stops 2 growth mechanisms:  it stops the formation of new blood vessels, and it also stops invasion.  Earlier work on an adult glioblastoma rat model looked very good so a human recurrent adult high grade glioma trial has started.  Our project will pay for the pre-clinical work using this new drug on a pediatric glioma rat model, to pave the way for a pediatric brain tumor trial! There are more details about the treatment at:

http://newsok.com/omrf-researchers-finding-some-hope-in-anti-brain-tumor-drug/article/3809147

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740